SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (111)2/6/2001 10:21:20 AM
From: nigel bates  Read Replies (1) | Respond to of 1022
 
....and they only paid $77m for ImmGenics. Not a bad deal.
<g>

nig



To: scaram(o)uche who wrote (111)2/7/2001 4:22:37 PM
From: nigel bates  Read Replies (2) | Respond to of 1022
 
Abgenix and Celltech

According to today's FT, Celltech were discussing licensing with ImmGenics, but ABGX were somewhat quicker off the mark. Royalties were described as "low double digit".

Too many more deals like this & I'll begin to seriously doubt the claim that UK biotechs are relatively undervalued.
<g>

nig



To: scaram(o)uche who wrote (111)2/12/2001 4:01:58 PM
From: Elmer  Read Replies (1) | Respond to of 1022
 
Hi Richard,
I was reading research reports this weekend (which is often harmful to my wealth) and came upon a passage that said that the FDA has approved 9 Monoclonal Antibodies so far. For $25, name all 9!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News